PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies

Abstract excerpt

The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with an increasing population of patients who develop acquired PARPi resistance. Coupled with those patients with primary PARPi resistance, there is an urgent need to better understand mechanisms of resistance and identify...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to Integrated Circuits and Semiconductor Failure Analysis
• Share to PARP inhibition in cancer therapy